<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236362</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-Ib-10</org_study_id>
    <nct_id>NCT04236362</nct_id>
  </id_info>
  <brief_title>A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer</brief_title>
  <official_title>A Phase Ib, Single Arm, Open-label Study of TQB2450 Combined With Anlotinib in Subjects With Relapsed / Refractory Gynecological Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, phase Ib clinical trial to evaluate the efficacy and safety&#xD;
      of TQB2450 combined with anlotinib in subjects with gynecological cancer, including 34&#xD;
      ovarian cancer，34 endometrial cancer，22 cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Time from tumor first assessment to CR or PR to first assessment to PD (Progressive Disease) or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Gynecological Cancer</condition>
  <arm_group>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>A multi-target receptor tyrosine kinase inhibitor</description>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understood and signed an informed consent form;&#xD;
&#xD;
          2. 18 years and older, male or female, Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status of 0 to 1, life expectancy ≥ 3 months;&#xD;
&#xD;
          3. Histologically confirmed, unresectable recurrent/metastatic advanced gynecologic&#xD;
             cancer, including ovarian, endometrial, and cervical cancer;&#xD;
&#xD;
          4. Subjects have received at least 1 line platinum-containing chemotherapy (minimum of 4&#xD;
             cycles of platinum-containing treatment) after tumor reduction, and meet any of the&#xD;
             following：Platinum-resistant or refractory patients, including patients who have&#xD;
             progressed or relapsed during previous platinum-containing chemotherapy regimens or&#xD;
             within 6 months after the end of platinum-containing chemotherapy;&#xD;
&#xD;
          5. At least one measurable lesion according to the RECIST 1.1;&#xD;
&#xD;
          6. The main organs function are normally;&#xD;
&#xD;
          7. Male or female subjects should agree to use an adequate method of contraception&#xD;
             starting with the first dose of study therapy through 6 months after the last dose of&#xD;
             study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or&#xD;
             breastfeeding women, and a negative pregnancy test are received within 7 days before&#xD;
             the randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has other non-epithelial ovarian tumors or borderline ovarian epithelial tumors;&#xD;
&#xD;
          2. Other malignant tumors that have appeared or are currently present within 5 years,&#xD;
             except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial&#xD;
             bladder tumors;&#xD;
&#xD;
          3. Has previously received immune drugs such as PD-1 / PD-L1, CTLA-4 or other tyrosine&#xD;
             kinase inhibitors such as anlotinib hydrochloride;&#xD;
&#xD;
          4. Has received bevacizumab within 28 days before the first dose;&#xD;
&#xD;
          5. Has received chemotherapy, surgery, radiotherapy, the last treatment from the first&#xD;
             dose less than 4 weeks, or oral targeted drugs for less than 5 half-lives, or oral&#xD;
             fluorouracil pyridine drugs for less than 14 days, mitomycin C and nitrosourea for&#xD;
             less than 6 weeks;&#xD;
&#xD;
          6. Expect to use any active vaccine against infectious diseases (such as influenza&#xD;
             vaccine, chickenpox vaccine, etc.) within 28 days before the first dose or during the&#xD;
             study period;&#xD;
&#xD;
          7. Patients diagnosed with immunodeficiency or undergoing systemic glucocorticoid therapy&#xD;
             or any other form of immunosuppressive therapy (dose&gt; 10mg / day prednisone or other&#xD;
             effective hormones) and continue to use it within 2 weeks before the first dose;&#xD;
&#xD;
          8. Active autoimmune diseases that require systemic treatment have occurred within 2&#xD;
             years before the first dose;&#xD;
&#xD;
          9. Subjects known to be allergic to the study drug or any of its excipients or have&#xD;
             experienced a severe allergic reaction to other monoclonal antibodies;&#xD;
&#xD;
         10. Has uncontrollable symptoms of brain metastases, spinal cord compression, cancerous&#xD;
             meningitis;&#xD;
&#xD;
         11. Has any bleeding or bleeding event ≥ CTC AE Grade 3 or unhealed wounds, ulcers or&#xD;
             fractures within 4 weeks before the first dose;&#xD;
&#xD;
         12. Has clinically significant thyroid dysfunction before the first dose;&#xD;
&#xD;
         13. Has multiple factors affecting oral medication;&#xD;
&#xD;
         14. Has any severe acute complications before the first dose;&#xD;
&#xD;
         15. Has participated in other anti-tumor intervention clinical trials within 4 weeks&#xD;
             before the first medication;&#xD;
&#xD;
         16. According to the judgement of the researchers, there are other factors that may lead&#xD;
             to the termination of the study. For example, other serious diseases including mental&#xD;
             disorders need to be treated together, serious laboratory abnormalities, accompanied&#xD;
             by family or social factors, which will affect the safety of the subjects, or the&#xD;
             collection of data and samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Huang</last_name>
    <phone>020-87343014</phone>
    <email>huangxin@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The General Hospital of the People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunchang Jiao</last_name>
      <phone>13801380677</phone>
      <email>jiaosc@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Shunchang Jiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Chongqing University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhou</last_name>
      <phone>13708384529</phone>
      <email>qizhou9128@163.com</email>
    </contact>
    <investigator>
      <last_name>Qi Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Chang</last_name>
      <email>44025660@qq.com</email>
    </contact>
    <investigator>
      <last_name>Liu Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Huang</last_name>
      <phone>020-87343014</phone>
      <email>huangxin@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Xin Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Hospital of Qinhuangdao</name>
      <address>
        <city>Qinhuangdao</city>
        <state>Hebei</state>
        <zip>066000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Haihong</last_name>
      <email>jhh660625@sina.com</email>
    </contact>
    <investigator>
      <last_name>Jin Haihong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 10, 2021</last_update_submitted>
  <last_update_submitted_qc>January 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

